These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 17410150)

  • 1. Drug discovery: lessons from evolution.
    Warren J
    Br J Clin Pharmacol; 2011 Apr; 71(4):497-503. PubMed ID: 21395642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem-cell laws in China fall short.
    Nature; 2010 Oct; 467(7316):633. PubMed ID: 20930795
    [No Abstract]   [Full Text] [Related]  

  • 3. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 4. Poor enforcement could jeopardize China's drug innovation policy.
    Jia H
    Nat Biotechnol; 2006 Oct; 24(10):1182-3. PubMed ID: 17033642
    [No Abstract]   [Full Text] [Related]  

  • 5. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
    Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. China's deadly drug problem.
    Cyranoski D
    Nature; 2007 Apr; 446(7136):598-9. PubMed ID: 17410150
    [No Abstract]   [Full Text] [Related]  

  • 7. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.